Press Release Distribution
 

Members Login  |  Register  |  Why Join?   Subscribe to Newsletter Newsletter   RSS Feeds RSS Feeds

Video Releases    |    Pricing & Distribution Plans    |    Today's News    |    News By Category    |    News By Region    |    News By Date    |    Business Directory
All Press Releases for August 01, 2005 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version    Bookmark del.icio.us    Diggs



After reports of death from use of faulty pain patch - Duragesic - the FDA issues health advisory
LawyersandSettlements.com promotes free case evaluations by U.S. law firms for users adversely affected by the Duragesic pain patch. 
x-small text small text medium text large text


Duragesic Press ReleaseDuragesic Press ReleaseDownload the Press Release for review and publication: the Duragesic Pain Patch Recall
    /24-7PressRelease/ - VANCOUVER, BC, CANADA, August 01, 2005 - Over a year after the maker of Duragesic issued an urgent recall for the defective pain patches that were associated with 120 fatal reports, the FDA issues a health advisory and the drug company revises the drug's warning label.

Duragesic (fentanyl transdermal system CII) is an adhesive "pain patch" that is prescribed to persons suffering from chronic and/or debilitating pain such as arthritis. This pain medication or analgesic delivers a steady dose of fentanyl, a powerful opiate, to alleviate pain over an extended period of time (24-72 hours).

The drug's new "black box" warning label states, "Since the peak fentanyl levels occur between 24 and 72 hours of treatment, prescribers should be aware that serious or life threatening hypoventilation may occur, even in opioid- tolerant patients, during the initial application period." The FDA states that the abuse, misuse, or diversion of this pain patch could result in fatal respiratory illness and/or fatal cardiac arrest.

Negative effects and symptoms of a fentanyl overdose can occur when interacting with CNS Depressants or CYP3A4 Inhibitors, alcohol or drugs, or use of damaged or cut patches. Symptoms may include slow breathing, seizures, dizziness, weakness, loss of consciousness or coma. Continued exposure to uncontrolled amounts of fentanyl can lead to addiction and dependency.

The maker of Duragesic, Janssen L.P., specializes in pain management medication and developed this pain medication with their parent company, Johnson and Johnson and their pharmaceutical RandD department. Johnson and Johnson is the world's largest manufacturer of health care products with $47 billion in annual sales.

LawyersandSettlements.com is offering free legal evaluations for patients or their loved ones who have suffered any adverse side effects from the Duragesic Fentanyl Patch.

For more details about this product recall and potential class action lawsuit, visit https://www.lawyersandsettlements.com/case/duragesic

About Online Legal Services Ltd (OLS) and www.lawyersandsettlements.com
OLS is a privately held Internet marketing company. Lawyersandsettlements.com offers up-to-date information on legal news, class action lawsuits, personal injury cases, settlement details, product recalls, and more. Consumers can complete free case evaluations and subscribe to free newsletters. Justice for Everyone

Visit us at:
http://www.lawyersandsettlements.com/

Contact us at:
604-608-3435


---
Press release service and press release distribution provided by http://www.24-7pressrelease.com


# # #

Press Release Keywords:
Read more Press Releases from Tracy Laxdal:
Other Press Release Headlines:

Press Release Service & Press Release Distribution News Supplied By 24-7PressRelease.com
Press Release Contact Information:
Tracy Laxdal
www.lawyersandsettlements.com

Marketing Manager
E-Mail: Email us Here
Website: Visit Our Website
Disclaimer:
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release. We are unable to assist you with any information regarding this release. 24-7 Press Release disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.